WO2001003680A3 - Compounds for inhibiting diseases and preparing cells for transplantation - Google Patents

Compounds for inhibiting diseases and preparing cells for transplantation Download PDF

Info

Publication number
WO2001003680A3
WO2001003680A3 PCT/GB2000/002623 GB0002623W WO0103680A3 WO 2001003680 A3 WO2001003680 A3 WO 2001003680A3 GB 0002623 W GB0002623 W GB 0002623W WO 0103680 A3 WO0103680 A3 WO 0103680A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid
cells
amino
transplantation
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/002623
Other languages
French (fr)
Other versions
WO2001003680A2 (en
Inventor
Anne Clark
Paul Fraser
Bruce Verchere
Ajay Gupta
David Migneault
Walter Szarek
Donald Weaver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bellus Health Inc
Queens University at Kingston
Oxford University Innovation Ltd
Original Assignee
Queens University at Kingston
Neurochem Inc
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9916214.1A external-priority patent/GB9916214D0/en
Priority claimed from GBGB9916315.6A external-priority patent/GB9916315D0/en
Application filed by Queens University at Kingston, Neurochem Inc, Oxford University Innovation Ltd filed Critical Queens University at Kingston
Priority to HK03101761.2A priority Critical patent/HK1051137A1/en
Priority to AU59949/00A priority patent/AU5994900A/en
Priority to EP00946060A priority patent/EP1237547A2/en
Priority to CA002375628A priority patent/CA2375628A1/en
Publication of WO2001003680A2 publication Critical patent/WO2001003680A2/en
Anticipated expiration legal-status Critical
Publication of WO2001003680A3 publication Critical patent/WO2001003680A3/en
Priority to US11/265,537 priority patent/US20070015737A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Methods and compositions are provided for inhibiting, preventing and treating amyloid depositions, e.g. in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. Accordingly, the compositions and method of the invention are useful for inhibiting diabetes. The invention also provides a process for the preparation of cells suitable for transplantation into a mammal, which cells are capable of forming fibrils, said process comprising contacting the cells with an inhibitor of fibril formation. In particular the process prepares cells for use in a method of treating diabetes. Also provided are a culture medium comprising the inhibitor more particularly selected from the group consisting of 3-(3-hydroxy-1-propy)amino-1-propanesulfonic acid; DL-2-amino-5-phosphovaleric acid; 4-Phenyl-1-(3'-sulfopropyl)-1,2,3,6-tetrahydropyridine, cyclohexylsulfamic acid, O-phospho-L-serine, hexafluoroglutaric acid, 8-methoxyquinoline-5-sulfonic acid, 3-amino-2hydroxy-1-propanesulfonic acid, and 3-dimethylamino-1-propanesulfonic acid and 1,2,3,4-tetrahydroisoquinoleine.
PCT/GB2000/002623 1999-07-09 2000-07-07 Compounds for inhibiting diseases and preparing cells for transplantation Ceased WO2001003680A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
HK03101761.2A HK1051137A1 (en) 1999-07-09 2000-07-07 Compounds for inhibiting diseases and preparing cells for transplantation
AU59949/00A AU5994900A (en) 1999-07-09 2000-07-07 Compounds for inhibiting diseases and preparing cells for transplantation
EP00946060A EP1237547A2 (en) 1999-07-09 2000-07-07 Compounds for inhibiting diseases and preparing cells for transplantation
CA002375628A CA2375628A1 (en) 1999-07-09 2000-07-07 Compounds for inhibiting diseases and preparing cells for transplantation
US11/265,537 US20070015737A1 (en) 1999-07-09 2005-11-02 Compounds for inhibiting diseases and preparing cells for transplantation

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US14290799P 1999-07-09 1999-07-09
GB9916214.1 1999-07-09
US60/142,907 1999-07-09
GBGB9916214.1A GB9916214D0 (en) 1999-07-09 1999-07-09 Compounds for inhibiting diseases and preparing cells for transplantation
US14295399P 1999-07-12 1999-07-12
GBGB9916315.6A GB9916315D0 (en) 1999-07-12 1999-07-12 Compounds for inhibiting diseases and preparing cells for transplantation
US60/142,953 1999-07-12
GB9916315.6 1999-07-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/265,537 Continuation US20070015737A1 (en) 1999-07-09 2005-11-02 Compounds for inhibiting diseases and preparing cells for transplantation

Publications (2)

Publication Number Publication Date
WO2001003680A2 WO2001003680A2 (en) 2001-01-18
WO2001003680A3 true WO2001003680A3 (en) 2002-07-11

Family

ID=27451912

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/002623 Ceased WO2001003680A2 (en) 1999-07-09 2000-07-07 Compounds for inhibiting diseases and preparing cells for transplantation

Country Status (6)

Country Link
US (1) US20070015737A1 (en)
EP (1) EP1237547A2 (en)
AU (1) AU5994900A (en)
CA (1) CA2375628A1 (en)
HK (1) HK1051137A1 (en)
WO (1) WO2001003680A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US8859628B2 (en) 2003-02-27 2014-10-14 JoAnne McLaurin Method for preventing, treating and diagnosing disorders of protein aggregation

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US6562836B1 (en) 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
KR100897642B1 (en) 2002-12-20 2009-05-14 글락소 그룹 리미티드 Benzazepine Derivatives for the Treatment of Neurological Disorders
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
EP1644325A2 (en) * 2003-06-23 2006-04-12 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
CN100528840C (en) * 2003-06-23 2009-08-19 贝卢斯健康(国际）有限公司 Improved drug candidates and methods for their preparation
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7262223B2 (en) 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
BRPI0519243A2 (en) 2004-12-22 2009-01-06 Neurochem Int Ltd Methods and compositions for treating amyloid-related diseases
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
KR101594898B1 (en) 2005-07-15 2016-02-18 알바니 몰레큘라 리써치, 인크. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2007023389A2 (en) * 2005-07-21 2007-03-01 Neurochem (International) Limited Polymorphic forms of 3-amino-1-propanesulfonic acid
MX2008008213A (en) * 2005-12-22 2008-09-03 Neurochem Int Ltd Treatment of renal disorders, diabetic nephopathy and dyslipidemias.
DK2089417T3 (en) 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
CN101730529A (en) * 2006-12-22 2010-06-09 贝鲁斯健康(国际)有限公司 The method, chemical compound and the compositions that are used for the treatment of metabolic disease and diabetes
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2326619B1 (en) 2008-08-01 2019-02-27 Bioxiness Pharmaceuticals, Inc. Methionine analogs and methods of using same
AU2010247763B2 (en) * 2009-05-12 2015-12-24 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
WO2010132437A1 (en) 2009-05-12 2010-11-18 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
CU20130027A7 (en) 2013-02-28 2014-10-30 Ct De Neurociencias De Cuba CHEMICAL CHAPERONINS AS NEW MOLECULAR MODULATORS OF THE BETA PROTEIC AGGREGATION PRESENT IN THE CONFORMATIONAL DISEASES
HRP20241159T1 (en) 2020-02-07 2024-12-06 Gasherbrum Bio, Inc. HETEROCYCLIC AGONISTS FOR GLP-1
CN115361866B (en) * 2020-03-31 2025-07-18 株式会社Lg化学 Composition for protecting islet transplantation
CN116368140A (en) 2020-09-10 2023-06-30 加舒布鲁姆生物公司 Heterocyclic GLP-1 agonists
CN120957993A (en) 2023-02-16 2025-11-14 加舒布鲁姆生物公司 Heterocyclic GLP-1 agonists

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003714A2 (en) * 1991-08-27 1993-03-04 The Upjohn Company Method for treatment of metabolic disorders
WO1994022437A2 (en) * 1993-03-29 1994-10-13 Queen's University At Kingston Method for treating amyloidosis
WO1994027602A1 (en) * 1993-06-01 1994-12-08 Cortex Pharmaceuticals, Inc. Use of metabotropic receptor agonists in progressive neurodegenerative deseases
WO1996028187A1 (en) * 1995-03-15 1996-09-19 Queen's University At Kingston Method for treating amyloidosis
WO1996037612A1 (en) * 1995-05-23 1996-11-28 Pfizer Inc. Transgenic animal models for type ii diabetes mellitus
WO1998011923A1 (en) * 1996-09-20 1998-03-26 Baylor College Of Medicine Identification of agents that protect against inflammatory injury to neurons
WO1999040909A1 (en) * 1998-02-11 1999-08-19 Neurochem, Inc. Method for modulating macrophage activation
WO2000064420A2 (en) * 1999-04-28 2000-11-02 Queen's University At Kingston Compositions and methods for treating amyloidosis using sulphonate derivatives
WO2000071101A2 (en) * 1999-05-24 2000-11-30 Queen's University At Kingston Methods and compounds for inhibiting amyloid deposits

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318958A (en) * 1992-05-29 1994-06-07 Queen's University At Kingston Amyloid precursor protein
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US6703017B1 (en) * 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US5858326A (en) * 1995-06-06 1999-01-12 Neurochem, Inc. Methods of increasing amyloid deposition
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
US5869469A (en) * 1997-08-18 1999-02-09 Queen's University At Kingston Phosphonocarboxylate compounds for treating amyloidosis
US20020022657A1 (en) * 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
US6329356B1 (en) * 1998-04-10 2001-12-11 Neurochem, Inc. Phosphono-carboxylate compounds for treating amyloidosis
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
EP1251837A2 (en) * 1999-12-23 2002-10-30 Neurochem, Inc. Compounds and methods for modulating cerebral amyloid angiopathy
US20020115717A1 (en) * 2000-07-25 2002-08-22 Francine Gervais Amyloid targeting imaging agents and uses thereof
US7311893B2 (en) * 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
CN1774635A (en) * 2001-03-13 2006-05-17 金斯顿皇后大学 Anti-epileptogenic agents
US7501429B2 (en) * 2001-04-11 2009-03-10 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
JP2004536071A (en) * 2001-05-25 2004-12-02 クイーンズ　ユニバーシティ　アット　キングストン Heterocyclic beta amino acids and their use as antiepileptic agents
EA200400135A1 (en) * 2001-08-31 2004-08-26 Ньюрочем ( Интернэшнл) Лимитед USE OF AMIDINES DERIVATIVES FOR THE TREATMENT OF AMYLOIDOSIS
CA2399169A1 (en) * 2001-09-07 2003-03-07 Queen's University At Kingston Diagnostic methods for determining susceptibility to convulsive conditions
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050215562A1 (en) * 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders
US7253306B2 (en) * 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
HRP20140442T1 (en) * 2003-06-23 2014-07-04 Kiacta Sàrl Improved pharmaceutical drug candidates and methods for preparation thereof
US20050038000A1 (en) * 2003-06-23 2005-02-17 Xianqi Kong Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
WO2006008661A2 (en) * 2004-07-19 2006-01-26 Neurochem (International) Limited Diagnostic methods of multiple organ amyloidosis
EP1828111A2 (en) * 2004-11-12 2007-09-05 Neurochem (International) Limited Methods and fluorinated compositions for treating amyloid-related diseases
CN101103018A (en) * 2004-11-16 2008-01-09 神经化学（国际）有限公司 Compounds for the treatment of CNS and amyloid-related diseases
BRPI0519243A2 (en) * 2004-12-22 2009-01-06 Neurochem Int Ltd Methods and compositions for treating amyloid-related diseases
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003714A2 (en) * 1991-08-27 1993-03-04 The Upjohn Company Method for treatment of metabolic disorders
WO1994022437A2 (en) * 1993-03-29 1994-10-13 Queen's University At Kingston Method for treating amyloidosis
WO1994027602A1 (en) * 1993-06-01 1994-12-08 Cortex Pharmaceuticals, Inc. Use of metabotropic receptor agonists in progressive neurodegenerative deseases
WO1996028187A1 (en) * 1995-03-15 1996-09-19 Queen's University At Kingston Method for treating amyloidosis
WO1996037612A1 (en) * 1995-05-23 1996-11-28 Pfizer Inc. Transgenic animal models for type ii diabetes mellitus
WO1998011923A1 (en) * 1996-09-20 1998-03-26 Baylor College Of Medicine Identification of agents that protect against inflammatory injury to neurons
WO1999040909A1 (en) * 1998-02-11 1999-08-19 Neurochem, Inc. Method for modulating macrophage activation
WO2000064420A2 (en) * 1999-04-28 2000-11-02 Queen's University At Kingston Compositions and methods for treating amyloidosis using sulphonate derivatives
WO2000071101A2 (en) * 1999-05-24 2000-11-30 Queen's University At Kingston Methods and compounds for inhibiting amyloid deposits

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"USE OF METABOTROPIC AGONISTS IN PROGRESSIVE NEURODEGENERATIVE DISEASES", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 5, no. 5, 1995, pages 491 - 493, XP001012270, ISSN: 1354-3776 *
COPANI A ET AL: "ACTIVATION OF METABOTROPIC GLUTAMATE RECEPTORS PROTECTS CULTURED NEURONS AGAINST APOPTOSIS INDUCED BY beta-AMYLOID PEPTIDE", MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 5, no. 47, 1995, pages 890 - 897, XP002079923, ISSN: 0026-895X *
HUTCHINGS R ET AL: "The effect of excitotoxin antagonists on ibotenic acid-induced alteration of APP mRNA hippocampal expression.", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 47, no. 12B, 1995, British Pharmaceutical Conference 1995: Science Proceedings of the 132nd Meeting;Warwick, England, UK; September 15-18, 1995, pages 1131, XP002079922, ISSN: 0022-3573 *
PACHE D M ET AL: "EFFECT OF SELECTIVE EXCITATORY AMINO ACID ANTAGONISTS ON EXCITOTOXIN-INDUCED CHANGES IN APP MRNA EXPRESSION", PHARMACOLOGY REVIEWS AND COMMUNICATIONS, GORDON AND BREACH, CH, vol. 10, no. 3, 1999, pages 205 - 212, XP001014486 *
SCHWARCZ R. ET AL: "Excitatory aminoacid antagonists provide a therapeutic approach to neurological disorders.", LANCET, (1985) 2/8447 (140-143). CODEN: LANCAO, XP001030857 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859628B2 (en) 2003-02-27 2014-10-14 JoAnne McLaurin Method for preventing, treating and diagnosing disorders of protein aggregation
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases

Also Published As

Publication number Publication date
CA2375628A1 (en) 2001-01-18
EP1237547A2 (en) 2002-09-11
HK1051137A1 (en) 2003-07-25
AU5994900A (en) 2001-01-30
WO2001003680A2 (en) 2001-01-18
US20070015737A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
WO2001003680A3 (en) Compounds for inhibiting diseases and preparing cells for transplantation
WO2000071101A3 (en) Methods and compounds for inhibiting amyloid deposits
Stiller et al. Functional unit of the RNA polymerase II C-terminal domain lies within heptapeptide pairs
WO2001019798A3 (en) Inhibitors of factor xa
WO2001019788A3 (en) BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
Mehta et al. The future of keratoplasty: cell-based therapy, regenerative medicine, bioengineering keratoplasty, gene therapy
PL328094A1 (en) Conformingly restricted aromatic inhibitors triglycerides carrying chromosome protein and method of obtaining such inhibitors
MY120745A (en) Novel form of s-omeprazole
AU5030298A (en) Method of treating a mammal having a disease characterised by an overproduction or an upregulated production of TNF-alpha using biologically active compounds as inhibitors of TNF-alpha secretion
DE69311130D1 (en) ARYL PROPIONIC ACID DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND ITS USE AS AN ANALGETIC
WO2000071510A3 (en) INHIBITORS OF FACTOR Xa
DE69907210D1 (en) GLUCOCORTICOID AND THYROIDHORMONE RECEPTOR LIGANDS FOR THE TREATMENT OF METABOLISM DISEASES
Ferrari et al. Transplanted dopamine neurons derived from primate ES cells preferentially innervate DARPP‐32 striatal progenitors within the graft
US20250263752A1 (en) Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
WO2003030886A3 (en) Allylamides useful in the treatment of alzheimer's disease
DK0782569T3 (en) Racemization procedure used in the preparation of levobupivacaine and analogs thereof
PT989858E (en) COMPOUNDS IMITATING THE INHIBITORS OF CD28 / CTLA-PHARMACEUTICAL COMPOSITIONS MADE FROM THOSE REFERRED TO, AND A METHOD OF USING THOSE REFERENCES
BG104603A (en) 5-[4-[2-(n-methyl-n-(2-pyridyl)amino) ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, hydrate as pharmaceutical
WO2001047956A3 (en) Method for obtaining proteins having improved functional characteristics
CA2386231A1 (en) Membrane translocating peptide drug delivery system
AU2002356991A1 (en) Amino acid derivatives useful for the treatment of alzheimer's disease
ATE279424T1 (en) NEW COMPOUNDS KF-1040 AND METHOD FOR THEIR PRODUCTION
EP1206452B1 (en) Novel method for preparing benzoperhydroisoindole compounds
Jones et al. Attenuation of bone morphogenetic protein signaling during amphibian limb development results in the generation of stage‐specific defects
Malassagne et al. Hypodermin A, a new inhibitor of human complement for the prevention of xenogeneic hyperacute rejection

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2375628

Country of ref document: CA

Ref country code: CA

Ref document number: 2375628

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000946060

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000946060

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP